On February 9, 2021, the U.S. Food and Drug Administration (FDA) granted regular approval to cemiplimab-rwlc for patients with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI) or for whom a HHI is not appropriate and granted accelerated approval to cemiplimab-rwlc for patients with metastatic basal cell carxinoma previously treated with a HHI or for whom a HHI is not appropriate.
Read the FDA announcement.
Read Sanofi and Regeneron's announcements.
Posted 2/10/21
Recognizing the critical role advanced practice providers and allied health professionals play in the care continuum, the American Oncology Network provides infrastructure, leadership, and professional growth opportunities to empower these members of the cancer care team to practice at the top of their license.
